This proposed project is focused on determining how molecular-level changes in mitochondrial enzymes and transporters that occur in heart disease affect overall cardiac function and determining how therapies may be targeted at the molecular level to improve function at the whole-organ level. The proposed strategy is to first characterize the mitochondrial metabolic network based on quenched kinetic measurements in suspensions of isolated mitochondria. Studies will be carried out using mitochondria obtained from both normal healthy hearts and hearts obtained from a genetic model of hypertension and cardiomyopathy. Large-scale metabolic kinetic measurements will be used to parameterize and validate detailed metabolic models for both the healthy and diseased states. The developed mitochondrial models will be integrated into cell-level models of cardiac en- ergy metabolism, and the cell-level models into a spatially distributed simulation of cardiac oxygen transport that effectively captures spatial gradients and heterogeneity in oxygenation of the myocardium. The resulting tissue-level model will be used for a number of applications: (1) to analyze data on substrate utilization in healthy and diseased states to determine if and how physiological control mechanisms fail in the setting of altered metabolic enzyme activity and expression in the diseased heart.
The aim here will be to un- derstand mechanisms leading to reduced capacity to oxidize both fatty acids and carbohydrates, and associ- ated reduction in energetic state, in heart disease; (2) to evaluate metabolic effects of therapeutic strategies tied to metabolic function. We will determine if the model can predict the action of several specific metabolic interventions.
The aim here is to develop a powerful platform for an engineering-based approach to under- standing and treating the metabolic effects of heart disease. These analyses may lead to identification of tar- gets or strategies for improving metabolic therapy; and (3) to evaluate if and how regulatory mechanisms re- spond differently to acute ischemia and recovery in the normal and disease cases. To realize these applications, we must first develop a rigorous simulation platform, integrated from the bot- tom-up. Specifically, we will start by obtaining kinetic data to identify the organelle-level model from ex vivo ex- periments (Aim 1). Here we propose to obtain (and make available) time-course kinetic data on 43 metabolic intermediates in response to protocols designed to probe the TCA cycle and -oxidation pathways. These data will be used in Aim 2 for model development, parameterization, and validation. Development and application of tissue-level modeling and simulation tools are pursued in Aim 3. Project Relevance to Public Health Mitochondrial dysfunction is implicated in many human diseases including cancer, Alzheimer's disease, Park- inson's disease, and heart disease. Metabolic dysfunction in the diseased heart limits the rate at which primary substrates can be oxidized to synthesize ATP necessary for ionic homeostasis and cardiac contraction. We propose to obtain large-scale kinetic data on cardiac cellular energetics and to use those data to develop vali- dated simulation-based tools to understand metabolic dysfunction in heart disease. In addition, our proposed tools for simulation of the pathophysiological operation of metabolic control mechanisms in heart disease may be used to guide clinical interventions aimed at modulation of cardiac energy metabolism.
|Mescam, Muriel; Vinnakota, Kalyan C; Beard, Daniel A (2011) Identification of the catalytic mechanism and estimation of kinetic parameters for fumarase. J Biol Chem 286:21100-9|
|Vinnakota, Kalyan C; Beard, Daniel A (2011) Kinetic analysis and design of experiments to identify the catalytic mechanism of the monocarboxylate transporter isoforms 4 and 1. Biophys J 100:369-80|
|Vinnakota, Kalyan C; Dash, Ranjan K; Beard, Daniel A (2011) Stimulatory effects of calcium on respiration and NAD(P)H synthesis in intact rat heart mitochondria utilizing physiological substrates cannot explain respiratory control in vivo. J Biol Chem 286:30816-22|
|Haumann, Johan; Dash, Ranjan K; Stowe, David F et al. (2010) Mitochondrial free [Ca2+] increases during ATP/ADP antiport and ADP phosphorylation: exploration of mechanisms. Biophys J 99:997-1006|
|Vinnakota, Kalyan C; Rusk, Joshua; Palmer, Lauren et al. (2010) Common phenotype of resting mouse extensor digitorum longus and soleus muscles: equal ATPase and glycolytic flux during transient anoxia. J Physiol 588:1961-83|
|Camara, Amadou K S; Lesnefsky, Edward J; Stowe, David F (2010) Potential therapeutic benefits of strategies directed to mitochondria. Antioxid Redox Signal 13:279-347|
|Vinnakota, Kalyan C; Beard, Daniel A; Dash, Ranjan K (2009) Design of experiments for identification of complex biochemical systems with applications to mitochondrial bioenergetics. Conf Proc IEEE Eng Med Biol Soc 2009:4171-4|